This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bio-Rad Rides on International Expansion Amid Cost Concerns
by Zacks Equity Research
Each of Bio-Rad's (BIO) key segments registers solid growth across three major geographies of America, Europe and Asia.
Bio-Rad Launches Serology Test to Detect Coronavirus Antibody
by Zacks Equity Research
Bio-Rad (BIO) launches a blood-based immunoassay kit to better detect antibodies in response to SARS-CoV-2 infection.
Hologic (HOLX) Posts Q2 Preliminary Results, Withdraws View
by Zacks Equity Research
Investors remain optimistic with Hologic's (HOLX) balanced segmental preliminary revenue results for second-quarter fiscal 2020.
Integra Releases Preliminary Q1 Results, Withdraws '20 View
by Zacks Equity Research
Integra (IART) unable to measure the magnitude of total loss it has to bear out of the coronavirus-led economic damages, and hence, withdraws the full-year guidance.
Medtronic (MDT) Demonstrates Global Growth Amid Cost Concerns
by Zacks Equity Research
Medtronic's (MDT) international Diabetes business registers solid growth on the continued adoption of MiniMed 670G in overseas markets.
Myriad Genetics' (MYGN) BRACAnalysis Gets Japan Reimbursement
by Zacks Equity Research
Myriad Genetics (MYGN) launches BRACAnalysis Diagnostic System in Japan, after receiving reimbursement for the system, which will enable easier identification of HBOC patients.
Here's Why You Should Hold on to Thermo Fisher (TMO) for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on its strong segmental growth in the fourth quarter of 2019.
Product Launches Aid Hill-Rom Amid Project Timing Issues
by Zacks Equity Research
Hill-Rom (HRC) plans to roll out five-six new products each year through 2022.
Here's Why You Should Add STERIS (STE) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about STERIS (STE) on its strong segmental growth in the third quarter of 2020.
Haemonetics (HAE) Buys enicor to Expand Testing Portfolio
by Zacks Equity Research
Haemonetics (HAE) expands its portfolio with the buyout of enicor. With the latter's whole blood coagulation testing system, the company will address a wider range of criticalities in medicine.
Align Technology Buys exocad to Expand Its Digital Platform
by Zacks Equity Research
Align Technology (ALGN) expands its portfolio with the buyout completion of exocad. This will help the company offer fully integrated workflows to dental labs and dental practices worldwide.
IDEXX's (IDXX) CAG Arm Grows Strong on Product Launches
by Zacks Equity Research
Product launches like Cornerstone, Neo, Animana aid IDEXX' (IDXX) CAG business.
Here's Why You Should Hold on to Teleflex (TFX) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Teleflex (TFX) on its strong segmental and international growth in the fourth quarter of 2019.
Why Is National Vision (EYE) Down 37% Since Last Earnings Report?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
National Vision (EYE): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
National Vision (EYE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
National Vision Grows on Positive Comps, Rising Costs a Woe
by Zacks Equity Research
National Vision's (EYE) positive comparable store sales (comps) growth story continues for 72 consecutive quarters.
National Vision (EYE) Rides on Robust Growth Across All Lines
by Zacks Equity Research
National Vision (EYE) continues to register strong segmental performances.
Teleflex Hits New 52-Week High: What's Driving the Rally?
by Zacks Equity Research
Teleflex (TFX) is optimistic about maintaining growth momentum on several recent developments.
Thermo Fisher Rides on New Product Suite, Currency Woes Stay
by Zacks Equity Research
Thermo Fisher Scientific (TMO) recently unveils a product suite comprising the TSQ Altis, Quantis MD mass spectrometers and Vanquish MD HPLC.
Masimo's Neonatal RD SET Pulse Oximetry Sensors Get FDA Nod
by Zacks Equity Research
Masimo (MASI) will cater to the whole prenatal patient population, with the recent FDA clearance within the SET pulse oximetry business.
Hologic (HOLX) Divests Cynosure to Focus on Women's Health
by Zacks Equity Research
Hologic (HOLX) expects to witness favorable outcomes from the sell-off of the Cynosure medical aesthetics business, which was its loss-making arm since 2017.
Here's Why You Should Add NuVasive Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about NuVasive (NUVA) on its stellar segmental performance in Q3.
Edwards (EW) Rides on Innovation Despite Regulatory Issues
by Zacks Equity Research
Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.
Product Launches Aid Intersect ENT (XENT) Despite Cost Woes
by Zacks Equity Research
Intersect ENT (XENT) recently closes its ENCORE study, a small 50-patient open label program designed to evaluate the safety of the repetitive use of SINUVA.
Bruker (BRKR) Rides High on Strong Nano Sales, New Buyouts
by Zacks Equity Research
Bruker (BRKR) is reaping solid synergy benefits from the acquisitions of Anasys, JPK and Alicona.